HEADER APOPTOSIS 30-NOV-06 2O2M TITLE SOLUTION STRUCTURE OF THE ANTI-APOPTOTIC PROTEIN BCL-XL IN TITLE 2 COMPLEX WITH AN ACYL-SULFONAMIDE-BASED LIGAND COMPND MOL_ID: 1; COMPND 2 MOLECULE: APOPTOSIS REGULATOR BCL-X; COMPND 3 CHAIN: A; COMPND 4 SYNONYM: BCL-2-LIKE 1 PROTEIN; COMPND 5 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: BCL2L1, BCL2L, BCLX; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET30B KEYWDS APOPTOSIS, COMPLEX, BCL, NMR EXPDTA SOLUTION NMR AUTHOR M.BRUNCKO,T.K.OOST,B.A.BELLI,H.DING,M.K.JOSEPH,A.KUNZER, AUTHOR 2 D.MARTINEAU,W.J.MCCLELLAN,M.MITTEN,S.C.NG,P.M.NIMMER, AUTHOR 3 T.OLTERSDORF,C.M.PARK,A.M.PETROS,A.R.SHOEMAKER,X.SONG, AUTHOR 4 X.WANG,M.D.WENDT,H.ZHANG,S.W.FESIK,S.H.ROSENBERG,S.W.ELMORE REVDAT 2 24-FEB-09 2O2M 1 VERSN REVDAT 1 27-FEB-07 2O2M 0 JRNL AUTH M.BRUNCKO,T.K.OOST,B.A.BELLI,H.DING,M.K.JOSEPH, JRNL AUTH 2 A.KUNZER,D.MARTINEAU,W.J.MCCLELLAN,M.MITTEN,S.C.NG, JRNL AUTH 3 P.M.NIMMER,T.OLTERSDORF,C.M.PARK,A.M.PETROS, JRNL AUTH 4 A.R.SHOEMAKER,X.SONG,X.WANG,M.D.WENDT,H.ZHANG, JRNL AUTH 5 S.W.FESIK,S.H.ROSENBERG,S.W.ELMORE JRNL TITL STUDIES LEADING TO POTENT, DUAL INHIBITORS OF JRNL TITL 2 BCL-2 AND BCL-XL. JRNL REF J.MED.CHEM. V. 50 641 2007 JRNL REFN ISSN 0022-2623 JRNL PMID 17256834 JRNL DOI 10.1021/JM061152T REMARK 1 REMARK 2 REMARK 2 RESOLUTION. NOT APPLICABLE. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER A. T. ETALL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2O2M COMPLIES WITH FORMAT V. 3.15, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 08-DEC-06. REMARK 100 THE RCSB ID CODE IS RCSB040608. REMARK 210 REMARK 210 EXPERIMENTAL DETAILS REMARK 210 EXPERIMENT TYPE : NMR REMARK 210 TEMPERATURE (KELVIN) : 303 REMARK 210 PH : 7.0 REMARK 210 IONIC STRENGTH : 50 MM SODIUM PHOSPHATE REMARK 210 PRESSURE : 1 ATM REMARK 210 SAMPLE CONTENTS : 50MM SODIUM PHOSPHATE BUFFER; REMARK 210 90% H2O, 10% D2O REMARK 210 REMARK 210 NMR EXPERIMENTS CONDUCTED : 3D_13C-SEPARATED_NOESY REMARK 210 SPECTROMETER FIELD STRENGTH : 600 MHZ, 800 MHZ REMARK 210 SPECTROMETER MODEL : DRX REMARK 210 SPECTROMETER MANUFACTURER : BRUKER REMARK 210 REMARK 210 STRUCTURE DETERMINATION. REMARK 210 SOFTWARE USED : NULL REMARK 210 METHOD USED : SIMULATED ANNEALING REMARK 210 REMARK 210 CONFORMERS, NUMBER CALCULATED : NULL REMARK 210 CONFORMERS, NUMBER SUBMITTED : 1 REMARK 210 CONFORMERS, SELECTION CRITERIA : NULL REMARK 210 REMARK 210 BEST REPRESENTATIVE CONFORMER IN THIS ENSEMBLE : 1 REMARK 210 REMARK 210 REMARK: NULL REMARK 215 REMARK 215 NMR STUDY REMARK 215 THE COORDINATES IN THIS ENTRY WERE GENERATED FROM SOLUTION REMARK 215 NMR DATA. PROTEIN DATA BANK CONVENTIONS REQUIRE THAT REMARK 215 CRYST1 AND SCALE RECORDS BE INCLUDED, BUT THE VALUES ON REMARK 215 THESE RECORDS ARE MEANINGLESS. REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 GLU A 162 CD GLU A 162 OE2 0.109 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 ASP A 193 CB - CG - OD2 ANGL. DEV. = -5.5 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 GLN A 7 -65.21 71.83 REMARK 500 TYR A 26 -174.74 -53.99 REMARK 500 ALA A 28 -173.36 173.50 REMARK 500 MET A 37 -78.82 63.53 REMARK 500 ALA A 38 -80.82 66.78 REMARK 500 TYR A 105 53.90 -97.52 REMARK 500 LEU A 116 119.30 -175.18 REMARK 500 HIS A 117 76.60 -115.27 REMARK 500 ASP A 137 45.91 -104.07 REMARK 500 MET A 163 66.94 -150.84 REMARK 500 ASN A 179 38.05 -99.60 REMARK 500 ASP A 180 39.23 -177.43 REMARK 500 HIS A 181 -36.28 175.89 REMARK 500 GLU A 188 30.05 -97.48 REMARK 500 ASN A 189 28.85 -145.67 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE LI0 A 1000 DBREF 2O2M A 6 27 UNP Q07817 BCLX_HUMAN 2 23 DBREF 2O2M A 37 200 UNP Q07817 BCLX_HUMAN 83 196 SEQADV 2O2M ALA A 28 UNP Q07817 INSERTION SEQADV 2O2M GLY A 29 UNP Q07817 INSERTION SEQADV 2O2M GLY A 25 UNP Q07817 INSERTION SEQADV 2O2M GLY A 31 UNP Q07817 INSERTION SEQADV 2O2M GLY A 32 UNP Q07817 INSERTION SEQADV 2O2M GLY A 33 UNP Q07817 INSERTION SEQADV 2O2M GLY A 29 UNP Q07817 INSERTION SEQADV 2O2M GLY A 30 UNP Q07817 INSERTION SEQADV 2O2M GLY A 31 UNP Q07817 INSERTION SEQRES 1 A 145 SER GLN SER ASN ARG GLU LEU VAL VAL ASP PHE LEU SER SEQRES 2 A 145 TYR LYS LEU SER GLN LYS GLY TYR SER ALA GLY GLY GLY SEQRES 3 A 145 GLY GLY GLY GLY GLY MET ALA ALA VAL LYS GLN ALA LEU SEQRES 4 A 145 ARG GLU ALA GLY ASP GLU PHE GLU LEU ARG TYR ARG ARG SEQRES 5 A 145 ALA PHE SER ASP LEU THR SER GLN LEU HIS ILE THR PRO SEQRES 6 A 145 GLY THR ALA TYR GLN SER PHE GLU GLN VAL VAL ASN GLU SEQRES 7 A 145 LEU PHE ARG ASP GLY VAL ASN TRP GLY ARG ILE VAL ALA SEQRES 8 A 145 PHE PHE SER PHE GLY GLY ALA LEU CYS VAL GLU SER VAL SEQRES 9 A 145 ASP LYS GLU MET GLN VAL LEU VAL SER ARG ILE ALA ALA SEQRES 10 A 145 TRP MET ALA THR TYR LEU ASN ASP HIS LEU GLU PRO TRP SEQRES 11 A 145 ILE GLN GLU ASN GLY GLY TRP ASP THR PHE VAL GLU LEU SEQRES 12 A 145 TYR GLY HET LI0 A1000 88 HETNAM LI0 4-(4-BENZYL-4-METHOXYPIPERIDIN-1-YL)-N-[(4-{[1,1- HETNAM 2 LI0 DIMETHYL-2-(PHENYLTHIO)ETHYL]AMINO}-3-NITROPHENYL) HETNAM 3 LI0 SULFONYL]BENZAMIDE FORMUL 2 LI0 C36 H40 N4 O6 S2 HELIX 1 1 GLN A 7 LYS A 24 1 18 HELIX 2 2 ALA A 38 TYR A 105 1 18 HELIX 3 3 TYR A 105 SER A 114 1 10 HELIX 4 4 ALA A 123 GLU A 133 1 11 HELIX 5 5 LEU A 134 GLY A 138 5 5 HELIX 6 6 ASN A 140 LYS A 161 1 22 HELIX 7 7 LEU A 166 ASN A 179 1 14 HELIX 8 8 LEU A 182 GLU A 188 1 7 HELIX 9 9 GLY A 190 TYR A 199 1 10 SITE 1 AC1 12 PHE A 101 TYR A 105 LEU A 112 GLU A 133 SITE 2 AC1 12 LEU A 134 ASN A 140 TRP A 141 GLY A 142 SITE 3 AC1 12 ARG A 143 VAL A 145 PHE A 195 TYR A 199 CRYST1 1.000 1.000 1.000 90.00 90.00 90.00 P 1 1 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 1.000000 0.000000 0.000000 0.00000 SCALE2 0.000000 1.000000 0.000000 0.00000 SCALE3 0.000000 0.000000 1.000000 0.00000 MASTER 121 0 1 9 0 0 3 6 0 0 0 12 END